In-house pharma lawyers share outside counsel criteria
Lawyers from Sanofi, BMS, Regeneron, and Roivant discuss their relationships with outside counsel, and emphasise the importance of diversity
At Managing IP’s US Patent Forum on April 3 in New York City, the topic of diversity kept cropping up.
To begin with, diversity is a “business imperative,” according to Henry Hadad, chief IP counsel at Bristol-Myers Squibb (BMS)...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.